What defines a sustainable biosimilar market?
What characterizes an ideal, sustainable biosimilar market that improves…
FYB201 successful in the MENA region
With its market launch in Jordan last year, approval and winning the government…
Formycon@Berenberg EU Opportunities
We are delighted to be at the Berenberg EU Opportunities Conference 2024 in…
Interview "der Aktionär"
In an interview with "Der Aktionär", Formycon CFO Enno Spillner talks about the…
The strength of diversity
We at Formycon believe that diversity and inclusion are the fundamental pillars…
Gedeon Richter becomes strategic investor of Formycon
“Robust supply and cost-competitive manufacturing are becoming increasingly…
FYB201 achieved 38% market share in the US in December 2023
Great news from the US: Uptake of our ranibizumab biosimilar FYB201/Cimerli® in…
